CAS ONLINE PRINTOUT 09/816,317

=> d his

(FILE 'HOME' ENTERED AT 08:11:23 ON 09 OCT 2003)

FILE 'REGISTRY' ENTERED AT 08:11:27 ON 09 OCT 2003
L1 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L2 STRUCTURE UPLOADED
L3 QUE L2 NOT L1
L4 SCREEN 2026 OR 2021 OR 2016 OR 973 OR 2127 OR 1993 OR 184
L5 STRUCTURE UPLOADED
L6 QUE L5 NOT L4
L7 38 S L6 FUL CSS

FILE 'CAPLUS' ENTERED AT 08:13:19 ON 09 OCT 2003
L8 343 S L7
L9 169063 S INFLAMM?
L10 138050 S CYTOKINE?
L11 58619 S ARTHRITIS OR PNACREATITIS OR LUPUS OR ENCEPHALOMYELITIS OR GL
L12 6640 S PANCREATITIS
L13 318151 S L11 OR L12 OR L10 OR L9
L14 3 S L13 AND L8

=> d l5
L5 HAS NO ANSWERS
L5 STR




G1 OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,t-BuO,X

G2 H,OH,MeO,X

Structure attributes must be viewed using STN Express query preparation.

=> d bib abs hitstr l14 1-3

L14 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 2002:977602 CAPLUS
DN 138:39143
TI Preparation of purines as inhibitors of phosphodiesterase VII (PDE7) for therapeutic use in treating T-cell mediated diseases
IN Vaccaro, Wayne; Roberge, Jacques Y.; Leftheris, Katerina; Pitts, William J.; Barbosa, Joseph
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 6

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 2002102314 | A2 | 20021227 | WO 2002-US19126 | 20020617 |
| | W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| | US 2003092721 | A1 | 20030515 | US 2002-173322 | 20020617 |
| | US 2003100571 | A1 | 20030529 | US 2002-173530 | 20020617 |
| PRAI | US 2001-299287P | P | 20010619 | | |
| | US 2002-368752P | P | 20020329 | | |

OS MARPAT 138:39143
GI




I




II




III

AB Purines, such as I and II [R1 = H, alkyl; R2 = heteroaryl, heterocyclyl, aryl; J = H, halogen, alkoxy, alkenyloxy, alkynyloxy, aryloxy, heteroaryloxy, cycloalkyloxy, etc.; Y = alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, cycloalkyl; Z = alkoxy, alkylthio, alkylamino, alkylsulfonylamino aryloxy, arylthio, arylamino, arylsulfonylamino, heteroaryloxy, heteroarylthio, heteroarylamino, heteroarylsulfonylamino, etc.], were prepd. for pharmaceutical use as PDE7 inhibitors for use in treating T-cell mediated diseases, such as transplant rejection, rheumatoid **arthritis**, and juvenile diabetes. Thus, purine II (Z = 3-pyridinylmethyl) was prepd. starting from 2,6-dichloro-7-ethylpurine, 2-amino-4-methyl-5-thiazolecarboxylic acid Et ester and 3-pyridinemethanamine. The prepd. purines were assayed for inhibition of PDE in Hut78 cell lysate using an SPA specific for cAMP and were assayed for inhibition of prodn. and secretion of TNF.alpha. for leukocytes. Pharmaceutical compns. were also discussed.

IT **119999-69-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of purines as inhibitors of phosphodiesterase VII (PDE7) for therapeutic use in treating T-cell mediated diseases)

CAS ONLINE PRINTOUT 09/816,317

RN 119999-69-8 CAPLUS
CN 1-Naphthalenamine, 1,2,3,4-tetrahydro-6,7-dimethoxy- (9CI) (CA INDEX NAME)




L14 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN
AN 1998:543041 CAPLUS
DN 129:161424
TI Preparation of (S)-2-amino-6-fluoro-7-methoxytetraline for treatment of **septic** shock.
IN Moretti, Gian Piero; Foresta, Piero
PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
SO PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9833762 | A1 | 19980806 | WO 1998-IT11 | 19980128 |
| | W: JP, US | | | | |
| | RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE | | | | |
| | EP 968174 | A1 | 20000105 | EP 1998-902173 | 19980128 |
| | EP 968174 | B1 | 20030122 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI | | | | |
| | JP 2001509802 | T2 | 20010724 | JP 1998-532693 | 19980128 |
| | AT 231486 | E | 20030215 | AT 1998-902173 | 19980128 |
| | ES 2190581 | T3 | 20030801 | ES 1998-902173 | 19980128 |
| | US 6225501 | B1 | 20010501 | US 1999-341762 | 19990716 |
| PRAI | IT 1997-RM50 | A | 19970203 | | |
| | WO 1998-IT11 | W | 19980128 | | |

GI



I

AB S(-)-amino-6-fluoro-7-methoxytetraline (I) and salts thereof were prepd. Thus, L-aspartic acid was refluxed with (F3CCO)2O in CF3CO2H to give 95% N-trifluoroacetylaspartic anhydride. This was stirred with 2-fluoroanisole and AlCl3 to give 78.3% (S)-4-(3-fluoro-4-methoxyphenyl)-4-oxo-2-(N-trifluoroacetyl)aminobutanoic acid. The latter was treated with Et3SiH in refluxing CF3CO2H to give 75% (S)-4-(3-fluoro-4-methoxyphenyl)-2-(N-trifluoroacetyl)aminobutanoic acid. The acid in CH2Cl2 was treated with PCl5 and then with AlCl3 at -20.degree.-reflux to give 60.4% (S)-(N-trifluoroacetyl)amino-6-fluoro-7-methoxy-1-tetralone. Treatment of the latter with Et3SiH in BF3.Et2O at 0.degree.-room temp. gave 78.63%

(S)-(N-trifluoroacetyl)amino-6-fluoro-7-methoxytetraline. This was refluxed with K2CO3 in MeOH/H2O to give 52.8% I.HCl (ST 1214). ST 1214 at 6 mg/kg i.v. in mice reduced lethality induced by E. coli or S. typhosa LPS by 37% and 65%, resp.

IT **211173-67-0P**, (S)-2-Amino-6-fluoro-7-methoxytetraline
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (S)-2-amino-6-fluoro-7-methoxytetraline for treatment of **septic** shock)

RN 211173-67-0 CAPLUS

CN 2-Naphthalenamine, 6-fluoro-1,2,3,4-tetrahydro-7-methoxy-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS on STN

AN 1996:649632 CAPLUS

DN 125:266047

TI Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of **septic** shock, and antipyretic and anti-**inflammatory** pharmaceutical compositions

IN Foresta, Piero; Ruggiero, Vito

PA Sigma-Tau Industrie Farmaceutiche Riunite S.P.A., Italy

SO Eur. Pat. Appl., 16 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | EP 730861 | A1 | 19960911 | EP 1996-102860 | 19960226 |
| | EP 730861 | B1 | 20000802 | | |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE | | | | |
| | AT 195072 | E | 20000815 | AT 1996-102860 | 19960226 |
| | ES 2150034 | T3 | 20001116 | ES 1996-102860 | 19960226 |
| | US 5591777 | A | 19970107 | US 1996-607452 | 19960227 |
| | TW 471967 | B | 20020111 | TW 1996-85102443 | 19960229 |
| | CA 2171081 | AA | 19960910 | CA 1996-2171081 | 19960305 |
| | ZA 9601897 | A | 19960912 | ZA 1996-1897 | 19960308 |
| | JP 08268884 | A2 | 19961015 | JP 1996-53075 | 19960311 |
| PRAI | IT 1995-RM143 | A | 19950309 | | |

OS MARPAT 125:266047

AB The use of 6,7-substituted-2-aminotetralines (e.g. 2-amino-6-fluoro-7-methoxytetraline) is disclosed for prepg. pharmaceutical compns. useful for the treatment of **septic** shock and having anti-**inflammatory** and antipyretic activities. Oral administration of 2-amino-6-fluoro-7-methoxytetraline (ST 626) at doses of 10, 20, and 50 mg/kg was able to decrease Brewer's yeast-induced pyrexia, as evaluated by rectal temp. measurements. Moreover, edema, developing as a consequence of the treatment with the phlogistic agent, was kept at lower values following treatment with ST 626.

CAS ONLINE PRINTOUT 09/816,317

IT **140914-59-6**, ST 626
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(aminotetralines for pharmaceutical compns. useful for treatment of **septic** shock and as antipyretics and **inflammation** inhibitors)
RN 140914-59-6 CAPLUS
CN 2-Naphthalenamine, 6-fluoro-1,2,3,4-tetrahydro-7-methoxy- (9CI) (CA INDEX NAME)




=>

CAS ONLINE PRINTOUT 09/816,317

=> d his

```
     (FILE 'HOME' ENTERED AT 08:11:23 ON 09 OCT 2003)

     FILE 'REGISTRY' ENTERED AT 08:11:27 ON 09 OCT 2003
L1                SCREEN 2026 OR  2021 OR  2016 OR  973 OR  2127 OR  1993 OR  184
L2                STRUCTURE UPLOADED
L3                QUE L2 NOT L1
L4                SCREEN 2026 OR  2021 OR  2016 OR  973 OR  2127 OR  1993 OR  184
L5                STRUCTURE UPLOADED
L6                QUE L5 NOT L4
L7             38 S L6 FUL CSS

     FILE 'CAPLUS' ENTERED AT 08:13:19 ON 09 OCT 2003
L8            343 S L7
L9         169063 S INFLAMM?
L10        138050 S CYTOKINE?
L11         58619 S ARTHRITIS OR PNACREATITIS OR LUPUS OR ENCEPHALOMYELITIS OR GL
L12          6640 S PANCREATITIS
L13        318151 S L11 OR L12 OR L10 OR L9
L14             3 S L13 AND L8
                  SELECT PN L14 1-3

     FILE 'USPATFULL' ENTERED AT 08:18:09 ON 09 OCT 2003
L15             4 S E1-E17

     FILE 'REGISTRY' ENTERED AT 08:20:56 ON 09 OCT 2003
                  E ST1275/CN
                  E ST 1275/CN
                  E 2-AMINO-6-FLUORO-7-METHYLTETRALINE/CN

     FILE 'REGISTRY' ENTERED AT 08:33:03 ON 09 OCT 2003
L16               SCREEN 2026 OR  2021 OR  2016 OR  973 OR  2127 OR  1993 OR  184
L17               STRUCTURE UPLOADED
L18               QUE L17 NOT L16
L19             0 S L17 CSS
L20               SCREEN 2026 OR  2021 OR  2016 OR  973 OR  2127 OR  1993 OR  184
L21               STRUCTURE UPLOADED
L22               QUE L21 NOT L20
L23             4 S L22 CSS
L24            23 S L22 CSS FUL

     FILE 'CAPLUS' ENTERED AT 08:35:23 ON 09 OCT 2003
L25           325 S L24
L26             2 S L25 AND L13

     FILE 'REGISTRY' ENTERED AT 08:43:49 ON 09 OCT 2003
L27               SCREEN 963
L28               SCREEN 2026 OR  2021 OR  2016 OR  973 OR  2127 OR  1993 OR  184
L29               STRUCTURE UPLOADED
L30               QUE L29 AND L27 NOT L28
L31             0 S L30 CSS
L32             0 S L30 CSS FUL

     FILE 'BEILSTEIN' ENTERED AT 08:44:55 ON 09 OCT 2003
L33             0 S L29
L34             0 S L29 FUL

     FILE 'REGISTRY' ENTERED AT 08:46:48 ON 09 OCT 2003
L35             0 S L29
L36             4 S L29 FUL
```

CAS ONLINE PRINTOUT 09/816,317

=> d l29
L29 HAS NO ANSWERS
L29 STR




G1 OH,MeO,EtO,n-PrO,i-PrO,n-BuO,i-BuO,t-BuO,X,Ak
G2 H,OH,MeO,X

Structure attributes must be viewed using STN Express query preparation.

=> d ide bib abs 1-4

L36 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN
RN 221384-94-7 REGISTRY
CN 2-Naphthalenamine, 6-fluoro-1,2,3,4-tetrahydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)
MF C11 H14 F N . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPATFULL




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 130:237373 CA
TI Preparation of 2-aminotetralines for the prevention and treatment of inflammatory and/or autoimmune pathologies.
IN Fanto, Nicola; Moretti, Gian Piero; Foresta, Piero
PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy
SO PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | WO 9915494 | A1 | 19990401 | WO 1998-IT252 | 19980922 |
| | W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| | RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| | CA 2303943 | AA | 19990401 | CA 1998-2303943 | 19980922 |
| | AU 9893662 | A1 | 19990412 | AU 1998-93662 | 19980922 |
| | AU 738565 | B2 | 20010920 | | |
| | EP 1017667 | A1 | 20000712 | EP 1998-946706 | 19980922 |
| | R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO | | | | |
| | BR 9812368 | A | 20000919 | BR 1998-12368 | 19980922 |
| | JP 2001517649 | T2 | 20011009 | JP 2000-512805 | 19980922 |
| | NZ 503492 | A | 20020828 | NZ 1998-503492 | 19980922 |
| | US 2002123652 | A1 | 20020905 | US 2000-533381 | 20000322 |
| | US 2003158266 | A1 | 20030821 | US 2001-816317 | 20010326 |
| PRAI | IT 1997-RM568 | 19970922 | | | |
| | WO 1998-IT252 | 19980922 | | | |
| | US 2000-533381 | 20000322 | | | |

GI




I

AB Title compds. [I; R, R1 = halo, OH, (substituted) alkoxy, alkanoyl, alkyl, carbamoyl, carbamoyloxy, amino, etc.; R2 = H, halo, OH, MeO; with provisos], and salts thereof, were prepd. Thus, (R)-(+)-2-amino-6-fluoro-7-hydroxytetralin hydrochloride (prepd. in several steps from D-aspartic acid and 2-fluoroanisole) at 18 mg/kg i.v. improved survival in E. coli LPS-treated mice by 44%.

RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L36 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN
RN 70153-83-2 REGISTRY
CN 1(2H)-Naphthalenone, 2-amino-6-chloro-3,4-dihydro-7-methyl-, hydrochloride (9CI) (CA INDEX NAME)
MF C11 H12 Cl N O . Cl H
LC STN Files: CA, CAPLUS



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 91:20185 CA
TI Cyclic aminoalcohols
IN Hiraoka, Masayuki; Fukami, Hideo; Fukumori, Satoshi; Mizusawa, Hidetoshi; Fujihara, Hiroshi; Yasui, Bompei
PA Funai Pharmaceutical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | JP 54003047 | A2 | 19790111 | JP 1977-67585 | 19770608 |
| | JP 60045179 | B4 | 19851008 | | |
| PRAI | JP 1977-67585 | | 19770608 | | |

GI



I



II



III



IV

AB Twenty-two title compds. I.HCl (R = aryloxy, aralkyl, aryl, cyclic alkyl, alkyl; R1 = H, alkyl, halo; or R R1 = alkylene) were prepd. by redn. of II or III or by hydrolysis of IV (R2 = alkyl, etc.). I had coronary vasodilating and heart muscle contraction inhibitory activities and are useful as remedies for angina pectoris (data given in the isolated guinea pig heart by Langendorff method). Thus, refluxing 3 g IV (R = PhO, R1 = H, R2 = Me) with 100 mL 0.1% HCl 12 h gave cis-I HCl (R = PhO, R1 = H).

L36 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN
RN 70153-48-9 REGISTRY
CN 1-Naphthalenol, 2-amino-6-chloro-1,2,3,4-tetrahydro-7-methyl-,

hydrochloride, trans- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H14 Cl N O . Cl H
LC STN Files: CA, CAPLUS

Relative stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 91:20185 CA
TI Cyclic aminoalcohols
IN Hiraoka, Masayuki; Fukami, Hideo; Fukumori, Satoshi; Mizusawa, Hidetoshi; Fujihara, Hiroshi; Yasui, Bompei
PA Funai Pharmaceutical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| PI JP 54003047 | A2 | 19790111 | JP 1977-67585 | 19770608 |
| JP 60045179 | B4 | 19851008 | | |
| PRAI JP 1977-67585 | 19770608 | | | |

GI




I




II




III




IV

AB Twenty-two title compds. I.HCl (R = aryloxy, aralkyl, aryl, cyclic alkyl,

alkyl; R1 = H, alkyl, halo; or R R1 = alkylene) were prepd. by redn. of II or III or by hydrolysis of IV (R2 = alkyl, etc.). I had coronary vasodilating and heart muscle contraction inhibitory activities and are useful as remedies for angina pectoris (data given in the isolated guinea pig heart by Langendorff method). Thus, refluxing 3 g IV (R = PhO, R1 = H, R2 = Me) with 100 mL 0.1% HCl 12 h gave cis-I HCl (R = PhO, R1 = H).

L36 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2003 ACS on STN
RN 70153-39-8 REGISTRY
CN 1-Naphthalenol, 2-amino-6-chloro-1,2,3,4-tetrahydro-7-methyl-, hydrochloride, cis- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C11 H14 Cl N O . Cl H
LC STN Files: CA, CAPLUS

Relative stereochemistry.




● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 91:20185 CA
TI Cyclic aminoalcohols
IN Hiraoka, Masayuki; Fukami, Hideo; Fukumori, Satoshi; Mizusawa, Hidetoshi; Fujihara, Hiroshi; Yasui, Bompei
PA Funai Pharmaceutical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

| | PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|---|
| PI | JP 54003047 | A2 | 19790111 | JP 1977-67585 | 19770608 |
| | JP 60045179 | B4 | 19851008 | | |

PRAI JP 1977-67585 19770608
GI

CAS ONLINE PRINTOUT 09/816,317




I




II




III




IV

AB Twenty-two title compds. I.HCl (R = aryloxy, aralkyl, aryl, cyclic alkyl, alkyl; R1 = H, alkyl, halo; or R R1 = alkylene) were prepd. by redn. of II or III or by hydrolysis of IV (R2 = alkyl, etc.). I had coronary vasodilating and heart muscle contraction inhibitory activities and are useful as remedies for angina pectoris (data given in the isolated guinea pig heart by Langendorff method). Thus, refluxing 3 g IV (R = PhO, R1 = H, R2 = Me) with 100 mL 0.1% HCl 12 h gave cis-I HCl (R = PhO, R1 = H).

=>